Piezo Motion’s Miniature Rotary Motor Gets a Big Upgrade
LAKEWOOD RANCH, Fla. (July 29, 2022) –– Piezo Motion, a Brain Scientific (OTCQB:BRSF) company, today announced an important update to its popular line of miniature rotary piezoelectric motors (the ‘RAS Series’).
The new addition to the RAS motor family (Model # RAS4P2) features almost twice the torque (4.5 mN.m) and fifty percent (50%) more speed (900 rpm) compared to the previous models while still maintaining the exceptional overall performance offered by the RAS series.
Piezo Motion’s signature rotary motor, built around a patented piezoelectric principle, overcomes the limitations of conventional high-precision DC stepper motors.
“Our latest addition to the RAS family provides exceptional resolution, fast response time, and an ultra-smooth motion; without the vibrational interference caused by traditional DC stepper motors,” said Dr. Mark Broderick, president of Piezo Motion. “Manufactured from lightweight reinforced engineering thermoplastics, and with a rotor diameter of just 11.2 mm, the new RAS combines high-performance in a lightweight design with exceptional energy-efficiency; characteristics that are essential for many medical device and high-tech applications.”
Piezo Motion’s multifaceted rotary and linear motors are built with technology that provides a stable, accurate motor designed specifically for original equipment manufacturers (OEMs) that require ultimate performance and quality; but without the burden of high cost.
Piezo Motion motors are used globally for a variety of applications. These include laboratory instruments, biomedicine, optics, semiconductors, nanotechnology, and industrial applications.
About Piezo Motion
Piezo Motion (piezomotion.com), a Brain Scientific company, is a leader in precision motor technology with multimillion-dollar investments in research and development of affordable piezoelectric motors to meet, and exceed, the needs of today’s global markets. The company is committed to the development of innovative technology and motion products that enhance functionality in a multitude of applications. The company works with startups, OEMs, research institutions and industrial companies from around the world, empowering the visionaries behind their products.
About Brain Scientific
Brain Scientific (brainscientific.com) is a medical technology company with multiple patents and FDA-cleared products. Brain Scientific is committed to developing next-gen solutions that advance the future of neurodiagnostic and OEM medical devices. Brain Scientific has two product lines covering neurology and precision motion. The NeuroCap and NeuroEEG are smart neurological diagnostic devices that simplify administration, shorten scan time, and cut costs. The Piezo Motion product line consists of ultra-efficient compact precision motors that will drive the next generation of medical devices. To learn more about Brain Scientific’s corporate strategy, products, or investor relations, please visit brainscientific.com.
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements may include, without limitation, statements regarding (i) the plans and objectives of management for future operations, including plans or objectives relating to the design, development and commercialization of EEG products and services and piezo motor technology; (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items; (iii) the company’s future financial performance; (iv) the successful integration of Piezo Motion with and into Brain Scientific; and (v) the assumptions underlying or relating to any statement described in points (i), (ii), (iii) or (iv) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the company’s current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, over many of which the company has no control. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the company’s inability to obtain additional financing; the significant length of time and resources associated with the development of products and related insufficient cash flows and resulting illiquidity; the company’s inability to expand its business; significant government regulation of medical devices and the healthcare industry; lack of product diversification; volatility in the price of the company’s raw materials; and the failure to implement the company’s business plans or strategies. Some of these and other factors are identified and described in more detail in the company’s filings with the SEC. The company does not undertake to update these forward-looking statements.